Literature DB >> 20809262

BRCA1 and BRCA2 families and the risk of skin cancer.

Ophira M Ginsburg1, Charmaine Kim-Sing, William D Foulkes, Parviz Ghadirian, Henry T Lynch, Ping Sun, Steven A Narod.   

Abstract

BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma skin cancer. We followed 2729 women with a BRCA1 or BRCA2 mutation for an average of 5.0 years. These women were asked to report new cases of cancer diagnosed in themselves or in their family. The risks of skin cancer were compared for probands with BRCA1 and BRCA2 mutations. Of 1779 women with a BRCA1 mutation, 29 developed skin cancer in the follow-up period (1.6%). Of the 950 women with a BRCA2 mutation, 28 developed skin cancer (3.0%) (OR = 1.83 for BRCA2 versus BRCA1; 95% CI 1.08-3.10; P = 0.02). The odds ratio for basal cell carcinoma was higher (OR = 3.8; 95% CI 1.5-9.4; P = 0.002). BRCA2 mutation carriers are at increased risk for skin cancer, compared with BRCA1 carriers, in particular for basal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809262     DOI: 10.1007/s10689-010-9377-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  45 in total

1.  Re: On the use of familial aggregation in population-based case probands for calculating penetrance.

Authors:  Wylie Burke; Melissa Austin
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

2.  Breast cancer risks for BRCA1/2 carriers.

Authors:  Sholom Wacholder; Jeffery P Struewing; Patricia Hartge; Mark H Greene; Margaret A Tucker
Journal:  Science       Date:  2004-12-24       Impact factor: 47.728

3.  BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.

Authors:  H A Shih; K L Nathanson; S Seal; N Collins; M R Stratton; T R Rebbeck; B L Weber
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

4.  BRCA2 mutation in Icelandic prostate cancer patients.

Authors:  S Sigurdsson; S Thorlacius; J Tomasson; L Tryggvadottir; K Benediktsdottir; J E Eyfjörd; E Jonsson
Journal:  J Mol Med (Berl)       Date:  1997-10       Impact factor: 4.599

5.  Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.

Authors:  J Lorenzo Bermejo; K Hemminki
Journal:  Ann Oncol       Date:  2004-12       Impact factor: 32.976

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

Authors:  Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  On the use of familial aggregation in population-based case probands for calculating penetrance.

Authors:  Colin B Begg
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

10.  Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.

Authors:  Paolo Aretini; Emma D'Andrea; Barbara Pasini; Alessandra Viel; Renato Mariani Costantini; Laura Cortesi; Enrico Ricevuto; Simona Agata; Roberta Bisegna; Mauro Boiocchi; Maria Adelaide Caligo; Luigi Chieco-Bianchi; Giovanna Cipollini; Rosella Crucianelli; Cristina D'Amico; Massimo Federico; Chiara Ghimenti; Clelia De Giacomi; Arcangela De Nicolo; Lara Della Puppa; Sergio Ferrari; Corrado Ficorella; Davide Iandolo; Siranoush Manoukian; Paolo Marchetti; Fabio Marroni; Chiara Menin; Marco Montagna; Laura Ottini; Valeria Pensotti; Marco Pierotti; Paolo Radice; Manuela Santarosa; Vittorio Silingardi; Daniela Turchetti; Generoso Bevilacqua; Silvano Presciuttini
Journal:  Breast Cancer Res Treat       Date:  2003-09       Impact factor: 4.872

View more
  15 in total

1.  Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

Authors:  Peter A Johansson; Vaishnavi Nathan; Lauren M Bourke; Jane M Palmer; Tongwu Zhang; Judith Symmons; Madeleine Howlie; Ann-Marie Patch; Jazlyn Read; Elizabeth A Holland; Helen Schmid; Sunil Warrier; William Glasson; Veronica Höiom; Karin Wadt; Göran Jönsson; Håkan Olsson; Christian Ingvar; Graham Mann; Kevin M Brown; Nicholas K Hayward; Antonia L Pritchard
Journal:  Melanoma Res       Date:  2019-10       Impact factor: 3.599

Review 2.  Ultraviolet Radiation Exposure and Its Impact on Skin Cancer Risk.

Authors:  Meg Watson; Dawn M Holman; Maryellen Maguire-Eisen
Journal:  Semin Oncol Nurs       Date:  2016-07-29       Impact factor: 2.315

Review 3.  Skin cancer risk in BRCA1/2 mutation carriers.

Authors:  P V Gumaste; L A Penn; R M Cymerman; T Kirchhoff; D Polsky; B McLellan
Journal:  Br J Dermatol       Date:  2015-04-29       Impact factor: 9.302

4.  Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma.

Authors:  N Sabbaghian; R Kyle; A Hao; D Hogg; M Tischkowitz
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

5.  Incidence of other cancer diagnoses in women with breast cancer: a retrospective cohort study with 42,248 women.

Authors:  Ivan Nikolov; Karel Kostev; Matthias Kalder
Journal:  Breast Cancer Res Treat       Date:  2022-07-12       Impact factor: 4.624

6.  Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Women's Health Initiative observational study.

Authors:  Mary Pressler; Carol A Rosenberg; Benjamin A Derman; Philip Greenland; Janardan Khandekar; Rebecca J Rodabough; Anne McTiernan; Michael S Simon
Journal:  Breast Cancer Res Treat       Date:  2013-06-13       Impact factor: 4.872

7.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.

Authors:  A Moran; C O'Hara; S Khan; L Shack; E Woodward; E R Maher; F Lalloo; D G R Evans
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

8.  Keratinocytes from Gorlin Syndrome-induced pluripotent stem cells are resistant against UV radiation.

Authors:  Nana Morita; Shoko Onodera; Yuriko Nakamura; Takashi Nakamura; Shin-Ichi Takahashi; Takeshi Nomura; Toshifumi Azuma
Journal:  Med Mol Morphol       Date:  2020-08-20       Impact factor: 2.309

9.  From BRCA1 to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes.

Authors:  Emma R Woodward; Elke M van Veen; D Gareth Evans
Journal:  Breast Care (Basel)       Date:  2021-03-31       Impact factor: 2.860

10.  Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary.

Authors:  Jae Myoung Noh; Doo Ho Choi; Hyejin Baek; Seok Jin Nam; Jeong Eon Lee; Jong Won Kim; Chang-Seok Ki; Won Park; Seung Jae Huh
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.